EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, PharmAust's enterprise value is A$69.61 Mil.
PharmAust's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.91 Mil. Therefore, PharmAust's EV-to-Revenue for today is 76.58.
The historical rank and industry rank for PharmAust's EV-to-Revenue or its related term are showing as below:
ASX:PAA'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.18 Med: 6.09 Max: 42.61
Current: 76.59
During the past 13 years, the highest EV-to-Revenue of PharmAust was 42.61. The lowest was 1.18. And the median was 6.09.
ASX:PAA's EV-to-Revenue is ranked worse than 81.43% of 1034
companies
in the Biotechnology industry
Industry Median: 7.98
vs ASX:PAA: 76.59
As of today (2024-05-30), PharmAust's stock price is A$0.185.
PharmAust's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00. Therefore, PharmAust's PS Ratio for today is 92.50.
PharmAust EV-to-Revenue Historical Data
The historical data trend for PharmAust's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PharmAust's EV-to-Revenue
For the Biotechnology subindustry, PharmAust's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmAust's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PharmAust's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where PharmAust's EV-to-Revenue falls into.
PharmAust's current Enterprise Value is A$69.61 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PharmAust's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.91 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmAust's share price for today is A$0.185.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmAust EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of PharmAust's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
PharmAust Ltd operates as a drug discovery and development company in Australia, Switzerland, and internationally. It develops drug discovery intellectual property for the treatment of various cancers in humans and animals. The company offers Monepantel and Albendazole, which are in Phase II clinical trials for the treatment of cancer. It also provides medicinal and synthetic chemistry services on a contract basis to the drug discovery and pharmaceutical industries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:PAA has been successfully added to your 